Literature DB >> 26205991

A New Guideline on Treatment of Hypertension in Those with Coronary Artery Disease: Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension About Treatment of Hypertension in Patients with Coronary Artery Disease.

Garry L R Jennings1.   

Abstract

Hypertension is a major risk factor for coronary artery disease (CAD) and the two frequently coexist. The peak cardiology and hypertension societies of the United States recently published new guidelines on the treatment of hypertension in people with CAD. The guidelines update those previously issued eight years previously in the light of new trial data. However, for the most part they will validate what cardiologists are already doing in these patients. The major change is resetting of the blood pressure general treatment target for most people with hypertension and CAD from 130/80mm Hg to 140/90mm Hg. It is arguable that the evidence supporting the new target is any stronger than that supporting the old. While this will remain controversial in the absence of good data on the relative benefits of different treatment targets in hypertension it is in line with trends from a number of other general hypertension guidelines.
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Absolute risk assessment; CAD; Coronary Artery Disease; Hypertension

Mesh:

Year:  2015        PMID: 26205991     DOI: 10.1016/j.hlc.2015.05.022

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  2 in total

1.  Primary and Secondary Prevention of CAD: A Review.

Authors:  Lindsay Short; Van T La; Mandira Patel; Ramdas G Pai
Journal:  Int J Angiol       Date:  2021-12-24

Review 2.  Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound.

Authors:  Xuefeng Su; Zhuoting Yao; Shengting Li; He Sun
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-13       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.